Enjoy complimentary customisation on priority with our Enterprise License!
The antimicrobial therapeutics market size of the market is forecast to increase by USD 51.4 billion at a CAGR of 5.63% between 2022 and 2027. The growth of the antimicrobial therapeutics market hinges on multiple factors, notably recent drug approvals and a robust pipeline, alongside initiatives from government agencies in the pharmaceutical industry. Additionally, increasing awareness about microbial diseases plays a pivotal role. With a surge in novel drug developments and supportive regulatory frameworks, the market is poised for expansion. Government interventions and funding further stimulate research and development efforts. Moreover, heightened awareness among healthcare professionals and the general public about the significance of combating microbial threats fuels the demand for advanced antimicrobial solutions, fostering market growth and innovation
To learn more about this report, Download Report Sample
The market continues to surge due to the persistent threat posed by fever-causing microorganisms such as bacteria. With a growing focus on medical and healthcare sectors, there's a pressing need for innovative solutions harnessing inorganic raw materials to combat infections effectively. Advancements in antimicrobial technology are leveraging Self-cleansing properties to enhance efficacy and durability. These antimicrobials play a pivotal role in preventing and treating various infectious diseases. As the demand for efficient antimicrobial solutions escalates, the market witnesses rapid expansion, driven by the urgency to address microbial threats while ensuring safety and efficacy in healthcare settings. The market is expected to grow due to the ongoing research and development in antimicrobial resistance and the introduction of new antimicrobial agents. The market is segmented based on product type, application, and end-user. Major players in the market include Pfizer, Merck & Co., Johnson & Johnson, AstraZeneca, and GlaxoSmithKline.
The market is a significant sector in the healthcare industry, focusing on the development, production, and distribution of agents to combat various microbial infections. These agents include antibiotics, antivirals, antifungals, and antiprotozoals. The market is driven by the increasing incidence of microbial infections, antibiotic resistance, and fungal infections. Fungicides and sanitizers are also essential components of the antimicrobial therapeutics market, used for microbial control in agriculture, food processing, and other industries. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.- The company conducts research and development, manufacturing, commercialization and offers innovative medicines and therapies globally. The company offers azactam injection which is used as medicine to treat symptoms of bacterial infections that occur in the blood and urinary tract.
The report also includes detailed analyses of the competitive landscape of the market and information about 15 market Companies , including:
Qualitative and quantitative analysis of Companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize Companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize Companies as dominant, leading, strong, tentative, and weak.
This report extensively covers market segmentation by application (antiviral, antibacterial, antifungal, and antiparasitic), end-user (pharmacies, hospitals and clinics, and research and academic institutes), and Geography (North America, Europe, Asia, and Rest of World (ROW)). Furthermore, the report includes historic market data from 2017 to 2021. The market encompasses the development, production, and distribution of pharmaceutical agents used to prevent or treat infections caused by microorganisms such as bacteria, viruses, fungi, and parasites. Pathogens pose a significant threat to public health, leading to an increasing demand for effective antimicrobial therapies. The demand is driven by factors such as the rising prevalence of infectious diseases, increasing antibiotic resistance, and growing awareness and initiatives to combat antimicrobial resistance. The market for antimicrobial therapeutics is diverse, with various classes of antimicrobials including antibiotics, antivirals, antifungals, and antiparasitics. The market is expected to grow significantly in the coming years due to the increasing burden of infectious diseases and the need for effective antimicrobial agents to combat them. The industry is also witnessing significant research and development efforts to discover new antimicrobial agents and improve existing ones to address the growing issue of antibiotic resistance.
The market share growth by the antiviral segment will be significant during the forecast period. During the forecast period, the antiviral segment is expected to grow moderately. The market encompasses solutions for inhibiting the growth of infection-causing microorganisms, including bacteria, fungi, algae, yeasts, mildew, and parasites. Untreated particles can lead to discoloration, unpleasant odors, and polymer degradation. To address these issues, antimicrobials offer enhanced properties such as dimensional stability, heat resistance, and chemical resistance. These benefits are crucial in various industries, including mining operations and the production of chemical solutions and products for industrial applications, nutrition, packaging & prints, and paint & coatings. In the context of personal care and hygiene, antimicrobials play a vital role in preventing the risk and spread of contaminant pathogens. Key antimicrobial elements include silver, copper, and zinc. Despite the market's growth potential, setbacks may arise due to the emergence of resistance and the need for continuous innovation to meet evolving industry demands.
Get a glance at the market contribution of various segments Request a PDF Sample
The antiviral segment was valued at USD 63.75 billion in 2017 and continued to grow until 2021. The robust pipeline of antiviral drugs is one of the major factors driving the market. Increased antiviral drug use results in the development of pipeline drugs and novel therapies with novel targets and mechanisms of action. For instance, Immune Response BioPharma's (Immune Response) REMUNE is in Phase II clinical trials for the treatment of HIV/AIDS in paediatric patients. Furthermore, Abivax SA (Abivax) developed ABX464 for the treatment of HIV. It is a small oral molecule that prevents HIV replication by removing viral reservoirs and lowering viral load in HIV patients. As a result, the market in focus is expected to experience accelerated growth momentum during the forecast period.
The market plays a pivotal role in combating Infectious Diseases through the development and distribution of antimicrobial therapeutics. This market encompasses various business segments, including Surface Technologies, Nutrition & Care, Agricultural Solutions, and Safety & Construction. Pharmaceuticals dominate this sector, supplying Antibacterial, Antiviral, Antifungal, and Antiparasitic agents. Key players in the Pharmaceutical Industry, such as Viatris, Mylan, Qpex Biopharma, and Merck, manufacture multidrug-resistant infection treatments like Remdesivir, Paxlovid, Cholestyramine, and combination therapies. Pew Charitable Trusts advocate for the responsible use of antimicrobial agents to mitigate Antibiotic Resistance. Additionally, industries like Plastics & Rubber, Pulp & Paper, Textile, Leather & Footwear, Transportation & Industrial, Electronics & Imaging, and Non-core sectors contribute to the market through the production of antimicrobial additives and products. Antimicrobial agents find applications in various sectors, including Nutrition & Biosciences and Safety & Construction. Key antimicrobial drugs include Antibacterial agents like Ciprofloxacin (against Enterobacteriaceae species such as aeruginosa and pneumoniae), Antiviral drugs like Remdesivir and Paxlovid, Antifungal drugs like Brexafemme and Olorofim, and Antiparasitic agents.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The market in North America is driven by the prevalence of infection-causing microorganisms, including bacteria, fungi, algae, yeasts, mildew, and parasites. Untreated particles can lead to discoloration, unpleasant odors, and polymer degradation. Enhanced antimicrobial properties, such as dimensional stability, heat resistance, and chemical resistance, are essential for various industries, including mining operations and chemical solution providers. The risk of contaminant pathogens spreading demands effective antimicrobial solutions. Key metals used include silver, copper, and zinc. Applications include industrial processes, nutrition, packaging & prints, paint & coatings, and personal care & hygiene. Setbacks, such as the outbreak of fever-causing microorganisms like influenza, HIV/AIDS, and COVID-19, increase market demand.
During the forecast period, the presence of strong reimbursement schemes for the treatment of deadly microbial diseases in the US is expected to drive the market. For instance, the Vaccines for Children (VFC) programme provides free vaccines for children who are uninsured, Medicaid-eligible, and under-insured. The Centers for Medicare and Medicaid Services in the United States reimburses all elderly patients with microbial infections such as HIV.
The market is a significant segment in the healthcare industry, focusing on the development and distribution of medicines to prevent or treat infections caused by microorganisms. These therapeutics include antibiotics, antivirals, antifungals, and antiparasitics. The market is driven by the increasing prevalence of infectious diseases, rising antibiotic resistance, and technological advancements in antimicrobial research and development. Infectious diseases such as tuberculosis, malaria, HIV/AIDS, and hepatitis continue to pose a global health threat, necessitating the need for effective antimicrobial therapeutics. Furthermore, the emergence of multi-drug resistant strains of bacteria and viruses has fueled the demand for new antimicrobial agents. The market is also influenced by regulatory policies, pricing pressures, and reimbursement scenarios. The use of advanced technologies such as gene editing, nanotechnology, and artificial intelligence in antimicrobial research and development is expected to revolutionize the market in the coming years.
The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.63% |
Market growth 2023-2027 |
USD 51.4 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
5.22 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key countries |
US, Germany, France, China, and Japan |
Competitive landscape |
Leading Companies , Market Positioning of Companies , Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Astellas Pharma Inc., Bavarian Nordic AS, Biocidium Biopharmaceuticals Inc., Bristol Myers Squibb Co., Cadila Pharmaceuticals Ltd., CSL Ltd., Emergent BioSolutions Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson Services Inc., Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Novartis AG, Novavax Inc., Pfizer Inc., Sanofi SA, and Wockhardt Ltd. |
Market dynamics |
Parent market analysis,market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our market growth analysis report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.